According to Junyao Health's announcement, the third quarter of 2026 achieved operating income of 372 million yuan, an increase of 13.09% over the previous year; a net loss of 237.432 million yuan. The first three quarters of 2026 achieved operating income of 1,210 million yuan, an increase of 10.52% over the previous year; net loss of 19.2441 million yuan, after deducting non-net loss of 24.1436 million yuan. The change in performance is mainly due to the impact of changes in the traditional room temperature lactic acid bacteria business due to changes in the consumption environment and consumption habits, a year-on-year decline in revenue and profit contributions, and an increase in marketing and R&D investment in the probiotic food business.

According to Junyao Health's announcement, the third quarter of 2026 achieved operating income of 372 million yuan, an increase of 13.09% over the previous year; a net loss of 237.432 million yuan. The first three quarters of 2026 achieved operating income of 1,210 million yuan, an increase of 10.52% over the previous year; net loss of 19.2441 million yuan, after deducting non-net loss of 24.1436 million yuan. The change in performance is mainly due to the impact of changes in the traditional room temperature lactic acid bacteria business due to changes in the consumption environment and consumption habits, a year-on-year decline in revenue and profit contributions, and an increase in marketing and R&D investment in the probiotic food business.